MaaT Pharma (MAAT) Stock Overview
A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MAAT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
MaaT Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.06 |
| 52 Week High | €8.62 |
| 52 Week Low | €3.55 |
| Beta | 0.22 |
| 1 Month Change | 43.20% |
| 3 Month Change | 84.82% |
| 1 Year Change | -3.29% |
| 3 Year Change | -20.85% |
| 5 Year Change | n/a |
| Change since IPO | -49.39% |
Recent News & Updates
Shareholder Returns
| MAAT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.2% | 1.4% | 0.4% |
| 1Y | -3.3% | 283.1% | 0.6% |
Return vs Industry: MAAT underperformed the French Biotechs industry which returned 301.3% over the past year.
Return vs Market: MAAT underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| MAAT volatility | |
|---|---|
| MAAT Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.1% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: MAAT's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: MAAT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 65 | Herve Affagard | www.maatpharma.com |
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improvement of survival at 12 months for patients with blood cancer receiving allogenic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors, as well as MaaT034 that optimize immune checkpoint inhibitor treatment. The company was incorporated in 2014 and is headquartered in Lyon, France.
MaaT Pharma SA Fundamentals Summary
| MAAT fundamental statistics | |
|---|---|
| Market cap | €132.85m |
| Earnings (TTM) | -€31.13m |
| Revenue (TTM) | €3.92m |
Is MAAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAAT income statement (TTM) | |
|---|---|
| Revenue | €3.92m |
| Cost of Revenue | €1.87m |
| Gross Profit | €2.06m |
| Other Expenses | €33.19m |
| Earnings | -€31.13m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 30, 2026
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 52.40% |
| Net Profit Margin | -793.80% |
| Debt/Equity Ratio | 107.1% |
How did MAAT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 08:30 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MaaT Pharma SA is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christian Orquera | First Berlin Equity Research GmbH |
| Emmanuel Parot | Gilbert Dupont |
| Stephanie Lefebvre | Gilbert Dupont |